Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ucMSCs for Non-viral ACLF
NCT07131540Phase 1Not yet recruiting
- Sponsor
- Institute of Liver and Biliary Sciences
- Start
- Jan 2026
- Primary completion
- Dec 2031
- Modality
- Stem Cell Therapies
01
Overview
Phase 1, open-label, single-arm trial of human umbilical cord mesenchymal stem cells in acute-on-chronic liver failure (ACLF), sponsored by Institute of Liver and Biliary Sciences. Primary endpoint: Safety of ucMSC infusion at Day 90. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
human umbilical cord mesenchymal stem cells
03
Conditions
acute-on-chronic liver failure (ACLF)
Beyond the preview
Go deeper on NCT07131540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07131540.